Ethylenediamine → 2-(5,6-dichloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(4-cyano-piperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-amide

HRID 245965Notes

Reaction equation

HRID 245965 reaction equation
[C:1]([CH:3]1[CH2:8][CH2:7][N:6]([C:9](=[O:46])[C@H:10]([NH:14][C:15]([C:17]2[C:25]3[C:20](=[N:21][CH:22]=[C:23]([C:26]4[C:34]5[C:29](=[CH:30][C:31]([Cl:36])=[C:32]([Cl:35])[CH:33]=5)[N:28]([CH3:37])[N:27]=4)[N:24]=3)[N:19](COCC[Si](C)(C)C)[CH:18]=2)=[O:16])[CH:11]2[CH2:13][CH2:12]2)[CH2:5][CH2:4]1)#[N:2].C(O)(C(F)(F)F)=O.C(N)CN>C(Cl)Cl>[C:1]([CH:3]1[CH2:8][CH2:7][N:6]([C:9](=[O:46])[C@H:10]([NH:14][C:15]([C:17]2[C:25]3[C:20](=[N:21][CH:22]=[C:23]([C:26]4[C:34]5[C:29](=[CH:30][C:31]([Cl:36])=[C:32]([Cl:35])[CH:33]=5)[N:28]([CH3:37])[N:27]=4)[N:24]=3)[NH:19][CH:18]=2)=[O:16])[CH:11]2[CH2:12][CH2:13]2)[CH2:5][CH2:4]1)#[N:2]

Participants

5

Reactant 3

HCID 3301EthylenediamineHCID 6422Trifluoroacetic acidHCID 712861802-(5,6-dichloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(4-cyano-piperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-amide

Product 1

HCID 712861882-(5,6-dichloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(4-cyano-piperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-amideYield 21%

Reagents, catalysts & solvents 1

HCID 6344DichloromethaneSolvent

Procedure

To a solution of 2-(5,6-dichloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(4-cyano-piperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-amide (130 mg, 0.19 mmol) in CH2Cl2 (4 mL) was added TFA (2.0 mL, 26.0 mmol). The reaction mixture was stirred at room temperature for 3 h then concentrated. The residue was redissolved in CH2Cl2 (4 mL) and ethylenediamine (0.4 mL, 5.92 mmol) was added. The reaction mixture was stirred at room temperature for 0.5 h then quenched with water and extracted with CH2Cl2 (3×). The combined organics were concentrated. The residue was purified by silica gel chromatography with 0% to 4% MeOH/CH2Cl2 (0.5% NH4OH) followed by trituration with Et2O to afford a white solid. This solid was further purified by recrystallization from MeOH/EtOAc to afford 22 mg of 2-(5,6-dichloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(4-cyano-piperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-amide as a white solid. MS: (M+Na)+=573; 1H NMR (DMSO-d6,300 MHz): δ (ppm) 12.92 (br. s., 1H), 9.14 (s, 1H), 8.88 (s, 1H), 8.69 (d, J=8.7 Hz, 1H), 8.46 (d, J=8.7 Hz, 1H), 8.24 (s, 1H), 4.93 (t, J=7.4 Hz, 1H), 4.18 (s, 3H), 3.45-3.94 (m, 3H), 3.15 (d, J=4.9 Hz, 2H), 1.35-1.91 (m, 5H), 0.51 (br. s., 4H).

Workup

  1. concentrationthen concentrated
  2. dissolutionThe residue was redissolved in CH2Cl2 (4 mL)
  3. stirringThe reaction mixture was stirred at room temperature for 0.5 h
  4. customthen quenched with water
  5. extractionextracted with CH2Cl2 (3×)
  6. concentrationThe combined organics were concentrated
  7. customThe residue was purified by silica gel chromatography with 0% to 4% MeOH/CH2Cl2 (0.5% NH4OH)
  8. customto afford a white solid
  9. customThis solid was further purified by recrystallization from MeOH/EtOAc

Sources & evidence

ORD record
ord-7d4bcf2d247b4471ae45f998906b4af4
Source dataset
uspto-grants-2014_02
Patent number
US08658646B2

Reaction notes

Loading…